I began my research on the investigation of transgenic avian embryos and oocyte culture in 2002. Then I transitioned to stem cell research in 2009, focusing on using pluripotent stem cells (PSCs) and mesenchymal stem cells (MSCs) for translational medicine. I have worked on stem cells for 15 years, with sophisticated skills in the derivation, identification, administration, and cryopreservation of PSCs. I am good at the culture and differentiation of PSCs, including induced pluripotent stem cells and embryonic stem cells, to somatic tissue cells (e.g., cardiomyocyte, neuron, MSCs, adipocyte, osteocyte, and chondrocyte) in the 3D culture system. Moreover, I administered the PSCs-derived somatic tissue cells (e.g., cardiomyocytes, neural progenitor cells (NPCs), and MSCs) in mice and cynomolgus for treating the disease models. Those models are spinal cord injury, experimental allergic encephalomyelitis (EAE), myocardial infarction, osteoarthritis, and wound healing). During these studies in the last six years, I recognized that biomaterials engineering may help stem cell survival, reduce immune rejection, and improve the therapeutic outcome of stem cells in vivo. Therefore, I am studying biomaterial engineering at the University of Maryland and working on stem cell engineering to develop new biomaterials-based technologies to increase the efficiency and quality of culturing and differentiating PSCs in 3D and enhance the efficacy and safety of stem cell-based therapies.